Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, ...

Reducing exposure to medicines is always a good thing if similar clinical outcomes can be achieved, and the study suggests it ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

Donald Trump has launched a new war, this time against pharmaceutical companies. He has signed an executive order to reduce ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...

GlobalData analysis predicts the global GLP-1RA market will reach $168bn by 2033, with Novo Nordisk and Eli Lilly to dominate ...

Analysts are still crunching the numbers on the impact of President Donald Trump's executive order from Monday on drug pricing. HSBC analyst Rajesh Kumar says a 20% price cut in government channels ...

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

The best metric is not weight, but a particularly toxic kind of fat.

A bold move by US President Donald Trump to slash the cost of prescription drugs in America has sent shockwaves through the ...